Important: New Login Process
We've updated our access and security system. The first time you log in, enter your work email, and we'll guide you through the process.
- If your organization uses Single Sign-On (SSO), you will be redirected to your company's login portal.
- If you log in with a username and password, you will be prompted to set a new password before accessing your account.
Go to the Login Page to get started.
We appreciate your cooperation during this transition. If you need assistance, please call +1 650-552-4224 or email support@biocentury.com.
- Company Profiles
- Target Profiles
- Product Profiles
Explore BCIQ profiles by entering a company name.
Galera Therapeutics Inc.
Headquarters: Malvern, PA, United States of America
Website: http://www.galeratx.com
Year Founded: 2009
Status: Public
Industry Sector: HealthTechnology
CEO: J. Mel Sorensen, MD
Number Of Employees: 7
Enterprise Value: $140,519,466
PE Ratio: -0.09
Exchange/Ticker 1: NASDAQ:GRTX
Exchange/Ticker 2: N/A
Latest Market Cap: $2,565,700
BioCentury | Sep 20, 2024
Management Tracks
Mark Bachleda takes the helm at Eyconis
Plus: Steve Caffé to lead regulatory affairs at Disc, and updates from Stalicla and AN Venture
BioCentury | Aug 15, 2024
Finance
No sleep for the biotech bear: Restructurings abound in August
At least 20 companies have trimmed pipelines, cut staff or otherwise re-jiggered strategies in past two weeks to extend runway
BioCentury | Aug 12, 2023
Regulation
Aug. 11 Quick Takes: Janssen gains prostate cancer approval
Plus: Atreca scraps lead program, turns to ADCs and updates from ALX Oncology, Hansoh-Antengene, Foghorn, Galera, Cascade
BioCentury | Jul 31, 2023
Data Byte
Over a dozen PDUFA dates on FDA’s August calendar
Decisions due next month include Sage’s depression therapy zuranolone and candidates for two ultra-rare diseases
BioCentury | Feb 15, 2023
Deals
Feb. 15 Quick Takes: Emergent deal to grow Bavarian Nordic footprint in U.S., Europe
Plus: Maxion raises series A to develop mAbs against ion channels, GPCRs and updates from Arrowhead, Moderna, Galera, Codagenix, Nanite
BioCentury | Oct 13, 2021
Management Tracks
Harler joins IGM as president of autoimmunity and inflammation business
Plus: Precigen, Transition Bio, Shoreline, Syros, Twist, Vor and more
BioCentury | Sep 29, 2021
Management Tracks
Rawat becomes president, CBO at Fusion
Plus: Sporos, Ajax, Nanocan and NeuroSense
BioCentury | Nov 7, 2019
Financial News
More weakness among IPOs as Galera, Centogene limp into marketplace
BioCentury | Oct 16, 2019
Financial News
Oct. 15 Financial Quick Takes: Phathom, Galera, J&J earnings, RTW Investments, Azitra, MaveriX
BioCentury | Oct 11, 2019
Company News
Management tracks: Chan leaving FDA’s China office; plus Galera, Aridis and Palladio
Items per page:
1 - 10 of 29